Sobi, or Swedish Orphan Biovitrum AB, is an international biopharmaceutical company specializing in treatments for rare diseases. It addresses unmet medical needs for individuals living with complex and often debilitating conditions, aiming to provide innovative therapies.
Understanding Sobi
Sobi operates as a global biopharmaceutical company, delivering medicines in over 30 countries. Its mission focuses on breakthrough innovations to improve daily life for people with rare diseases. The company’s origins trace back to the 1930s, evolving through mergers and acquisitions. Sobi maintains a strong focus on orphan drugs and specialty care.
Conditions Treated by Sobi Products
Sobi’s therapeutic focus includes hematology, immunology, and specialty care, encompassing rare genetic and metabolic diseases.
In hematology, Sobi provides treatments for hemophilia A and B. Its portfolio also includes treatments for thrombocytopenia, certain rare kidney diseases, diffuse large B-cell lymphoma, and myelofibrosis.
Within immunology, Sobi addresses auto-inflammatory and auto-immune conditions. Products include Gamifant (emapalumab-lzsg) for hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS), and Kineret (anakinra) for certain arthritis and rare immunological disorders. Sobi also offers Synagis (palivizumab) and Beyfortus, antibodies for respiratory syncytial virus (RSV).
Sobi’s specialty care portfolio includes therapies for rare genetic and metabolic diseases. For example, Orfadin (nitisinone) is used for an inherited metabolic disorder. Sobi continues research and development to provide innovative treatments for these underserved patient populations.
Accessing Sobi Therapies
Accessing specialized therapies from Sobi involves a process guided by healthcare professionals. A diagnosis from a qualified physician is the initial step, leading to a potential prescription for a Sobi product if it is deemed appropriate for the patient’s condition. These are specialized treatments that require careful medical guidance and oversight.
Sobi recognizes that navigating access to these therapies can be complex and offers patient support programs. These programs aim to assist patients with treatment access, provide education about their condition and therapy, and support adherence to treatment regimens. Such initiatives might include helping patients understand their insurance coverage or identifying additional resources. In certain situations, for life-threatening or seriously debilitating diseases where other treatment options are exhausted and clinical trial enrollment is not possible, Sobi has “Managed Access Programmes” that may allow access to investigational medicines prior to regulatory approval, provided specific criteria are met and local laws permit.